Home / Financial Report / May 2 Morning Report: GovCon Index Posts Weekly Decline, Sharp Gain for April

May 2 Morning Report: GovCon Index Posts Weekly Decline, Sharp Gain for April

GovConIndexDOWNThe GovCon Index posted a loss of 0.481 points to 76.361 Friday and closed the week with a decline amid the release of first-quarter earnings reports from large U.S. government contractors throughout the week.

GCI closed April as its third consecutive month with positive movement at a year-to-date gain of 5.24 percent.

Several of the largest GovCon companies reported first-quarter earnings and sales this week that topped Wall Street expectations, including Lockheed Martin (NYSE: LMT), General Dynamics (NYSE: GD) and Northrop Grumman (NYSE: NOC).

 

Top GovCon Index Net Gainers

Symbol Company $ Current Price Net Change ▴ % Change
LLL L-3 Communications* 131.53 +0.69 +0.53%
ICFI ICF International 39.37 +0.65 +1.68%
NOC Northrop Grumman* 206.26 +0.65 +0.32%
ACM AECOM 32.49 +0.22 +0.68%
BAESY BAE Systems 27.94 +0.02 +0.06%

* Also listed in the S&P 500 composite index

Top GovCon Index Percentage Gainers

Symbol Company $ Current Price Net Change % Change
ICFI ICF International 39.37 +0.65 +1.68%
ACM AECOM 32.49 +0.22 +0.68%
LLL L-3 Communications* 131.53 +0.69 +0.53%
NOC Northrop Grumman* 206.26 +0.65 +0.32%
I Intelsat 3.95 +0.01 +0.25%

Market Summary

Advancing GovCon Index Issues 6
Declining GovCon Index Issues 23
Unchanged GovCon Index Issues 1
Index Value Net Change % Change
GovCon Index 76.361 -0.481 -0.626%
S&P 500 2, 065.30 -10.51 -0.51%
Dow Jones Industrial Average 17, 773.64 -57.12 -0.32%
NASDAQ 4, 775.36 -29.93 -0.62%

Check Also

F5 to Buy Shape Security for $1B; Francois Locoh-Donou Quoted

F5 Networks (Nasdaq: FFIV) has agreed to acquire Santa Clara, Calif.-based Shape Security for approximately $1B in cash as both companies aim to help government and enterprise customers secure digital experience with integrated offerings.

Paratek Secures $169M Anthrax Antibiotic Development Contract Under HHS Project BioShield

The Department of Health and Human Services has awarded Paratek Pharmaceuticals a potential a five-year, $169M contract to further develop an antibiotic drug as a potential treatment for inhalation anthrax.